Lv11
40 积分 2026-05-12 加入
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
7天前
已完结
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
7天前
已完结
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
8天前
已完结
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
13天前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
13天前
已完结
Targeting the EGFR signalling pathway in metastatic colorectal cancer
1个月前
已完结
The landscape for therapeutic cancer vaccines
1个月前
已完结
皖公网安备34019202002308
